As Lilly (Eli) & Company (LLY) Stock Price Declined, Holder Park National Trimmed Position; Brown Advisory Has Trimmed Its Holding in Thermo Fisher Scientific (TMO) as Shares Rose

May 26, 2018 - By Marguerite Chambers

Thermo Fisher Scientific Inc. (NYSE:TMO) Logo

Brown Advisory Inc decreased its stake in Thermo Fisher Scientific Inc (TMO) by 3.4% based on its latest 2017Q4 regulatory filing with the SEC. Brown Advisory Inc sold 73,799 shares as the company’s stock rose 8.51% while stock markets declined. The institutional investor held 2.10M shares of the industrial machinery and components company at the end of 2017Q4, valued at $397.90 million, down from 2.17M at the end of the previous reported quarter. Brown Advisory Inc who had been investing in Thermo Fisher Scientific Inc for a number of months, seems to be less bullish one the $85.96B market cap company. The stock decreased 1.07% or $2.32 during the last trading session, reaching $213.65. About 929,238 shares traded. Thermo Fisher Scientific Inc. (NYSE:TMO) has risen 33.66% since May 26, 2017 and is uptrending. It has outperformed by 22.11% the S&P500.

Park National Corp decreased its stake in Lilly (Eli) & Company (LLY) by 14.44% based on its latest 2017Q4 regulatory filing with the SEC. Park National Corp sold 9,753 shares as the company’s stock declined 11.06% with the market. The institutional investor held 57,793 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $4.88M, down from 67,546 at the end of the previous reported quarter. Park National Corp who had been investing in Lilly (Eli) & Company for a number of months, seems to be less bullish one the $84.48B market cap company. The stock increased 0.07% or $0.06 during the last trading session, reaching $82.77. About 2.34M shares traded. Eli Lilly and Company (NYSE:LLY) has declined 10.19% since May 26, 2017 and is downtrending. It has underperformed by 21.74% the S&P500.

Among 19 analysts covering Thermo Fisher Scientific (NYSE:TMO), 18 have Buy rating, 0 Sell and 1 Hold. Therefore 95% are positive. Thermo Fisher Scientific had 63 analyst reports since July 24, 2015 according to SRatingsIntel. The company was maintained on Wednesday, April 11 by Morgan Stanley. The stock of Thermo Fisher Scientific Inc. (NYSE:TMO) has “Buy” rating given on Wednesday, October 25 by Cowen & Co. The rating was maintained by Jefferies with “Hold” on Tuesday, August 22. The firm earned “Hold” rating on Wednesday, September 27 by Jefferies. Jefferies maintained Thermo Fisher Scientific Inc. (NYSE:TMO) rating on Thursday, February 1. Jefferies has “Hold” rating and $230.0 target. Mizuho maintained Thermo Fisher Scientific Inc. (NYSE:TMO) rating on Friday, May 27. Mizuho has “Buy” rating and $170 target. The stock of Thermo Fisher Scientific Inc. (NYSE:TMO) earned “Hold” rating by Jefferies on Thursday, July 13. The company was maintained on Thursday, March 30 by Jefferies. Robert W. Baird maintained the shares of TMO in report on Thursday, January 18 with “Buy” rating. JP Morgan initiated the stock with “Overweight” rating in Thursday, September 22 report.

Brown Advisory Inc, which manages about $31.59 billion US Long portfolio, upped its stake in National Bk Hldgs Corp (NYSE:NBHC) by 111,968 shares to 1.12 million shares, valued at $36.27 million in 2017Q4, according to the filing. It also increased its holding in Ishares Tr (ACWI) by 10,769 shares in the quarter, for a total of 44,601 shares, and has risen its stake in Fortive Corp.

More news for Thermo Fisher Scientific Inc. (NYSE:TMO) were recently published by: Seekingalpha.com, which released: “Tracking Al Gore’s Generation Investment Management Portfolio – Q1 2018 Update” on May 26, 2018. Seekingalpha.com‘s article titled: “Thermo Fisher Scientific (TMO) Investor Presentation – Slideshow” and published on May 25, 2018 is yet another important article.

Since December 15, 2017, it had 0 insider buys, and 9 insider sales for $37.18 million activity. CASPER MARC N sold 80,000 shares worth $16.94 million. Another trade for 206 shares valued at $44,174 was made by HARRIS C MARTIN on Friday, May 18. 5,000 Thermo Fisher Scientific Inc. (NYSE:TMO) shares with value of $1.05 million were sold by Williamson Stephen. Shares for $1.31M were sold by Durbin Patrick M on Monday, February 5. 33,327 shares were sold by Herrema Gregory J., worth $7.32 million on Friday, February 2.

Analysts await Thermo Fisher Scientific Inc. (NYSE:TMO) to report earnings on July, 25. They expect $2.69 EPS, up 16.96% or $0.39 from last year’s $2.3 per share. TMO’s profit will be $1.08 billion for 19.86 P/E if the $2.69 EPS becomes a reality. After $2.50 actual EPS reported by Thermo Fisher Scientific Inc. for the previous quarter, Wall Street now forecasts 7.60% EPS growth.

Investors sentiment decreased to 0.91 in Q4 2017. Its down 0.05, from 0.96 in 2017Q3. It dropped, as 43 investors sold TMO shares while 410 reduced holdings. 93 funds opened positions while 319 raised stakes. 335.65 million shares or 0.74% more from 333.20 million shares in 2017Q3 were reported. Wealthtrust invested in 420 shares or 0.04% of the stock. First Pacific Advisors Llc owns 1.34 million shares. Schwab Charles Inv Inc reported 0.23% in Thermo Fisher Scientific Inc. (NYSE:TMO). Forte Cap Ltd Adv has 0.41% invested in Thermo Fisher Scientific Inc. (NYSE:TMO) for 7,183 shares. Keybank Natl Association Oh holds 0.62% or 566,147 shares in its portfolio. Capstone Advisors Ltd Llc accumulated 1,100 shares. Brown Advisory Securities reported 0.08% stake. Cibc Asset Inc invested 0.08% in Thermo Fisher Scientific Inc. (NYSE:TMO). Tennessee-based Laffer Invs has invested 0.75% in Thermo Fisher Scientific Inc. (NYSE:TMO). Field And Main Retail Bank invested in 2,886 shares or 0.53% of the stock. Guyasuta Advsr holds 2.64% or 122,668 shares. Cleararc Cap has invested 0.23% of its portfolio in Thermo Fisher Scientific Inc. (NYSE:TMO). Hudson Valley Invest Advsr Adv reported 2.03% stake. 55,020 are owned by Hightower Advisors Limited Co. Nomura Hldgs invested in 0.02% or 71,391 shares.

Since December 11, 2017, it had 0 insider purchases, and 11 sales for $48.49 million activity. $237,600 worth of Eli Lilly and Company (NYSE:LLY) was sold by Smiley Joshua L. Zakrowski Donald A had sold 876 shares worth $67,934 on Wednesday, February 21. $708,620 worth of stock was sold by Simmons Jeffrey N on Tuesday, May 1. 22,544 Eli Lilly and Company (NYSE:LLY) shares with value of $1.81 million were sold by Mahony Susan.

Among 22 analysts covering Eli Lilly and Company (NYSE:LLY), 13 have Buy rating, 1 Sell and 8 Hold. Therefore 59% are positive. Eli Lilly and Company had 103 analyst reports since July 23, 2015 according to SRatingsIntel. Credit Suisse upgraded Eli Lilly and Company (NYSE:LLY) rating on Friday, October 9. Credit Suisse has “Outperform” rating and $105 target. The company was maintained on Friday, April 13 by Jefferies. Jefferies maintained the stock with “Buy” rating in Friday, March 23 report. The stock has “Sell” rating by BMO Capital Markets on Wednesday, July 19. The stock has “Outperform” rating by Cowen & Co on Monday, August 24. The firm has “Hold” rating given on Thursday, August 31 by Leerink Swann. The stock of Eli Lilly and Company (NYSE:LLY) has “Buy” rating given on Monday, June 5 by Jefferies. Barclays Capital upgraded Eli Lilly and Company (NYSE:LLY) on Tuesday, December 1 to “Overweight” rating. The company was initiated on Thursday, August 27 by Berenberg. The rating was initiated by Atlantic Securities on Friday, December 18 with “Overweight”.

More notable recent Eli Lilly and Company (NYSE:LLY) news were published by: Bizjournals.com which released: “Big Peninsula biotech buyout means happy returns for Kleiner Perkins, other VCs” on May 10, 2018, also Streetinsider.com with their article: “Lilly (LLY) Says Taltz Received First US FDA Approval for Label Update to Include Data for Psoriasis Involving Genital …” published on May 22, 2018, Seekingalpha.com published: “FDA OKs expanded label for Lilly’s Taltz” on May 22, 2018. More interesting news about Eli Lilly and Company (NYSE:LLY) were released by: Streetinsider.com and their article: “Lilly (LLY) to Acquire AurKa Pharma for $110M Upfront, Plus up to $465M in Milestones” published on May 14, 2018 as well as Streetinsider.com‘s news article titled: “Lilly (LLY) Says Galcanezumab Met Primary Endpoint in Phase 3 Study for Prevention of Episodic Cluster Headache” with publication date: May 15, 2018.

Investors sentiment increased to 1.1 in Q4 2017. Its up 0.21, from 0.89 in 2017Q3. It is positive, as 42 investors sold LLY shares while 380 reduced holdings. 117 funds opened positions while 346 raised stakes. 827.08 million shares or 0.09% less from 827.83 million shares in 2017Q3 were reported. South State reported 0.29% of its portfolio in Eli Lilly and Company (NYSE:LLY). Jolley Asset Management Ltd Llc invested 0.12% in Eli Lilly and Company (NYSE:LLY). Haverford Tru reported 0.01% in Eli Lilly and Company (NYSE:LLY). Weatherly Asset Management Limited Partnership accumulated 327,825 shares. Finemark State Bank And holds 0.15% of its portfolio in Eli Lilly and Company (NYSE:LLY) for 28,274 shares. Aqr Management Ltd Company holds 0.18% of its portfolio in Eli Lilly and Company (NYSE:LLY) for 2.05 million shares. Winslow Evans And Crocker stated it has 8,346 shares. Poplar Forest Lc has 2.31% invested in Eli Lilly and Company (NYSE:LLY). Alpha Cubed Investments Ltd Liability Co has 0.03% invested in Eli Lilly and Company (NYSE:LLY). 29,944 are owned by Bb&T. Tcw Grp holds 0.02% of its portfolio in Eli Lilly and Company (NYSE:LLY) for 36,174 shares. 1,800 are held by Webster Bank N A. Prentiss Smith And Com holds 1,000 shares or 0.04% of its portfolio. Catawba Capital Management Va has 12,073 shares for 0.23% of their portfolio. Perkins Cap Management holds 1.7% or 20,900 shares in its portfolio.

Analysts await Eli Lilly and Company (NYSE:LLY) to report earnings on July, 24. They expect $1.34 earnings per share, up 20.72% or $0.23 from last year’s $1.11 per share. LLY’s profit will be $1.37 billion for 15.44 P/E if the $1.34 EPS becomes a reality. After $1.34 actual earnings per share reported by Eli Lilly and Company for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Park National Corp, which manages about $1.79B US Long portfolio, upped its stake in At&T Inc (NYSE:T) by 8,928 shares to 446,599 shares, valued at $17.36 million in 2017Q4, according to the filing. It also increased its holding in First Trust Dow Jones Global S (FGD) by 33,932 shares in the quarter, for a total of 189,985 shares, and has risen its stake in Bank Of America Corp (NYSE:BAC).

Thermo Fisher Scientific Inc. (NYSE:TMO) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>